nach oben

Current Rheumatology Reports

Erschienen in:

01.11.2021 | Systemic Lupus Erythematosus (G Tsokos, Section Editor)

TLR7 Signaling in Lupus B Cells: New Insights into Synergizing Factors and Downstream Signals

verfasst von: Anne B. Satterthwaite

Erschienen in: Current Rheumatology Reports | Ausgabe 11/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the Review

Systemic lupus erythematosus (SLE) is driven by nucleic acid-containing antigens that stimulate endosomal TLRs. We review new advances in our understanding of how TLR7 signaling in B cells drives autoimmunity.

Recent Findings

Pathogenic B cell responses to TLR7 engagement are shaped by the disease-associated cytokine environment. TLR7, IFNγ, and IL-21 together promote the formation of autoreactive germinal centers and the ABC/DN2 B cell subset. BAFF and type 1 IFNs enhance autoantibody production from transitional B cells in concert with TLR7. TLR7 signaling components STAT1, BANK1, IRF5, SLC15A4, and CXorf21/TASL are associated genetically with SLE and important for lupus development in mice, while role of T-bet is controversial. Proper control of TLR7 trafficking by UNC93B1, syntenin-1, and αvβ3 integrin is critical for preventing autoimmunity.

Summary

A better understanding of TLR7 signaling has revealed potential new therapeutic approaches for SLE, several of which are being tested in animal models or clinical trials.

Liu Z, Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med. 2012;18(6):871–82. https://doi.org/10.1038/nm.2752.CrossRefPubMedPubMedCentral

Atisha-Fregoso Y, Toz B, Diamond B. Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. J Clin Invest. 2021;131(12). https://doi.org/10.1172/JCI149095.

Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002;416(6881):603–7. https://doi.org/10.1038/416603a.CrossRefPubMed

Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005;202(9):1171–7. https://doi.org/10.1084/jem.20050630.CrossRefPubMedPubMedCentral

Subramanian S, Tus K, Li QZ, Wang A, Tian XH, Zhou J, et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U S A. 2006;103(26):9970–5. https://doi.org/10.1073/pnas.0603912103.CrossRefPubMedPubMedCentral

Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006;312(5780):1669–72. https://doi.org/10.1126/science.1124978.CrossRefPubMed

Deane JA, Pisitkun P, Barrett RS, Feigenbaum L, Town T, Ward JM, et al. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity. 2007;27(5):801–10. https://doi.org/10.1016/j.immuni.2007.09.009.CrossRefPubMedPubMedCentral

Yokogawa M, Takaishi M, Nakajima K, Kamijima R, Fujimoto C, Kataoka S, et al. Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erythematosus. Arthritis Rheumatol. 2014;66(3):694–706. https://doi.org/10.1002/art.38298.CrossRefPubMed

Chodisetti SB, Fike AJ, Domeier PP, Singh H, Choi NM, Corradetti C, et al. Type II but Not Type I IFN Signaling Is Indispensable for TLR7-Promoted Development of Autoreactive B Cells and Systemic Autoimmunity. J Immunol. 2020;204(4):796–809. https://doi.org/10.4049/jimmunol.1901175.CrossRefPubMed

10.

Hwang SH, Lee H, Yamamoto M, Jones LA, Dayalan J, Hopkins R, et al. B cell TLR7 expression drives anti-RNA autoantibody production and exacerbates disease in systemic lupus erythematosus-prone mice. J Immunol. 2012;189(12):5786–96. https://doi.org/10.4049/jimmunol.1202195.CrossRefPubMed

11.

Jackson SW, Scharping NE, Kolhatkar NS, Khim S, Schwartz MA, Li QZ, et al. Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation. J Immunol. 2014;192(10):4525–32. https://doi.org/10.4049/jimmunol.1400098.CrossRefPubMed

12.

Soni C, Wong EB, Domeier PP, Khan TN, Satoh T, Akira S, et al. B cell-intrinsic TLR7 signaling is essential for the development of spontaneous germinal centers. J Immunol. 2014;193(9):4400–14. https://doi.org/10.4049/jimmunol.1401720.CrossRefPubMed

13.

• Souyris M, Cenac C, Azar P, Daviaud D, Canivet A, Grunenwald S et al. TLR7 escapes X chromosome inactivation in immune cells. Sci Immunol. 2018;3(19). https://doi.org/10.1126/sciimmunol.aap8855. This study demonstrates that human immune cells can express TLR7 from both X chromosomes, and those cells that do are more responsive to TLR7 engagement. This suggests that increased TLR7 expression in females may contribute to the strong female predominance in SLE.

14.

Yu B, Qi Y, Li R, Shi Q, Satpathy AT, Chang HY. B cell-specific XIST complex enforces X-inactivation and restrains atypical B cells. Cell. 2021;184(7):1790–803.e17. https://doi.org/10.1016/j.cell.2021.02.015.

15.

Nundel K, Green NM, Shaffer AL, Moody KL, Busto P, Eilat D, et al. Cell-intrinsic expression of TLR9 in autoreactive B cells constrains BCR/TLR7-dependent responses. J Immunol. 2015;194(6):2504–12. https://doi.org/10.4049/jimmunol.1402425.CrossRefPubMed

16.

Tilstra JS, John S, Gordon RA, Leibler C, Kashgarian M, Bastacky S, et al. B cell-intrinsic TLR9 expression is protective in murine lupus. J Clin Invest. 2020;130(6):3172–87. https://doi.org/10.1172/JCI132328.CrossRefPubMedPubMedCentral

17.

Pollard KM, Cauvi DM, Toomey CB, Morris KV, Kono DH. Interferon-gamma and systemic autoimmunity. Discov Med. 2013;16(87):123–31.PubMedPubMedCentral

18.

Domeier PP, Chodisetti SB, Soni C, Schell SL, Elias MJ, Wong EB, et al. IFN-gamma receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity. J Exp Med. 2016;213(5):715–32. https://doi.org/10.1084/jem.20151722.CrossRefPubMedPubMedCentral

19.

Jackson SW, Jacobs HM, Arkatkar T, Dam EM, Scharping NE, Kolhatkar NS, et al. B cell IFN-gamma receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. J Exp Med. 2016;213(5):733–50. https://doi.org/10.1084/jem.20151724.CrossRefPubMedPubMedCentral

20.

Chodisetti SB, Fike AJ, Domeier PP, Choi NM, Soni C, Rahman ZSM. TLR7 Negatively Regulates B10 Cells Predominantly in an IFNgamma Signaling Dependent Manner. Front Immunol. 2020;11:1632. https://doi.org/10.3389/fimmu.2020.01632.CrossRefPubMedPubMedCentral

21.

Rubtsov AV, Rubtsova K, Kappler JW, Marrack P. TLR7 drives accumulation of ABCs and autoantibody production in autoimmune-prone mice. Immunol Res. 2013;55(1–3):210–6. https://doi.org/10.1007/s12026-012-8365-8.CrossRefPubMedPubMedCentral

22.

Du SW, Arkatkar T, Jacobs HM, Rawlings DJ, Jackson SW. Generation of functional murine CD11c(+) age-associated B cells in the absence of B cell T-bet expression. Eur J Immunol. 2019;49(1):170–8. https://doi.org/10.1002/eji.201847641.CrossRefPubMed

23.•

Ricker E, Manni M, Flores-Castro D, Jenkins D, Gupta S, Rivera-Correa J, et al. Altered function and differentiation of age-associated B cells contribute to the female bias in lupus mice. Nat Commun. 2021;12(1):4813. https://doi.org/10.1038/s41467-021-25102-8 . This study defines mechanisms required for ABC accumulation and function and highlights their responses to TLR7 as a contributer to sex bias in lupus.

24.

Rubtsov AV, Rubtsova K, Fischer A, Meehan RT, Gillis JZ, Kappler JW et al. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c(+) B-cell population is important for the development of autoimmunity. Blood. 2011;118(5):1305–15. https://doi.org/10.1182/blood-2011-01-331462.

25.

Rubtsova K, Rubtsov AV, Thurman JM, Mennona JM, Kappler JW, Marrack P. B cells expressing the transcription factor T-bet drive lupus-like autoimmunity. J Clin Invest. 2017;127(4):1392–404. https://doi.org/10.1172/JCI91250.CrossRefPubMedPubMedCentral

26.

Manni M, Gupta S, Ricker E, Chinenov Y, Park SH, Shi M, et al. Regulation of age-associated B cells by IRF5 in systemic autoimmunity. Nat Immunol. 2018;19(4):407–19. https://doi.org/10.1038/s41590-018-0056-8.CrossRefPubMedPubMedCentral

27.

Rubtsova K, Rubtsov AV, van Dyk LF, Kappler JW, Marrack P. T-box transcription factor T-bet, a key player in a unique type of B-cell activation essential for effective viral clearance. Proc Natl Acad Sci U S A. 2013;110(34):E3216–24. https://doi.org/10.1073/pnas.1312348110.CrossRefPubMedPubMedCentral

28.

Hao Y, O’Neill P, Naradikian MS, Scholz JL, Cancro MP. A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood. 2011;118(5):1294–304. https://doi.org/10.1182/blood-2011-01-330530.CrossRefPubMedPubMedCentral

29.

Cancro MP, Age-Associated B. Cells. Annu Rev Immunol. 2020;38:315–40. https://doi.org/10.1146/annurev-immunol-092419-031130.CrossRefPubMed

30.

Phalke S, Marrack P. Age (autoimmunity) associated B cells (ABCs) and their relatives. Curr Opin Immunol. 2018;55:75–80. https://doi.org/10.1016/j.coi.2018.09.007.CrossRefPubMed

31.•

Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X et al. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. Immunity. 2018;49(4):725–39.e6. https://doi.org/10.1016/j.immuni.2018.08.015. This report identifies DN2 cells as a CD11c+T-bet+ B cell population that is expanded in SLE and is particularly responsive to TLR7 stimulation.

32.•

Wang S, Wang J, Kumar V, Karnell JL, Naiman B, Gross PS, et al. IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c(hi)T-bet(+) B cells in SLE. Nat Commun. 2018;9(1):1758. https://doi.org/10.1038/s41467-018-03750-7. Here, a population of CD11c+T-bet+ B cells is shown to accumulate in SLE patients and differentiate into autoantibody secreting plasma cells.

33.•

Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019;20(7):902–14. https://doi.org/10.1038/s41590-019-0398-x. Single cell RNA-Seq defines multiple immune cell populations in lupus nephritis kidneys and indentifies relationships among them by developmental trajectory analysis.

34.

Rubtsov AV, Rubtsova K, Kappler JW, Jacobelli J, Friedman RS, Marrack P. CD11c-Expressing B Cells Are Located at the T Cell/B Cell Border in Spleen and Are Potent APCs. J Immunol. 2015;195(1):71–9. https://doi.org/10.4049/jimmunol.1500055.CrossRefPubMed

35.

Naradikian MS, Myles A, Beiting DP, Roberts KJ, Dawson L, Herati RS, et al. Cutting Edge: IL-4, IL-21, and IFN-gamma Interact To Govern T-bet and CD11c Expression in TLR-Activated B Cells. J Immunol. 2016;197(4):1023–8. https://doi.org/10.4049/jimmunol.1600522.CrossRefPubMed

36.

Zumaquero E, Stone SL, Scharer CD, Jenks SA, Nellore A, Mousseau B et al. IFNγ induces epigenetic programming of human T-bet(hi) B cells and promotes TLR7/8 and IL-21 induced differentiation. eLife. 2019;8:e41641. https://doi.org/10.7554/eLife.41641.

37.

Zhou S, Li Q, Zhou S, Zhao M, Lu L, Wu H, et al. A novel humanized cutaneous lupus erythematosus mouse model mediated by IL-21-induced age-associated B cells. J Autoimmun. 2021;123: 102686. https://doi.org/10.1016/j.jaut.2021.102686.CrossRefPubMed

38.

Giltiay NV, Chappell CP, Sun X, Kolhatkar N, Teal TH, Wiedeman AE, et al. Overexpression of TLR7 promotes cell-intrinsic expansion and autoantibody production by transitional T1 B cells. J Exp Med. 2013;210(12):2773–89. https://doi.org/10.1084/jem.20122798.CrossRefPubMedPubMedCentral

39.

Wang T, Marken J, Chen J, Tran VB, Li QZ, Li M, et al. High TLR7 Expression Drives the Expansion of CD19(+)CD24(hi)CD38(hi) Transitional B Cells and Autoantibody Production in SLE Patients. Front Immunol. 2019;10:1243. https://doi.org/10.3389/fimmu.2019.01243.CrossRefPubMedPubMedCentral

40.

Hamilton JA, Wu Q, Yang P, Luo B, Liu S, Hong H, et al. Cutting Edge: Endogenous IFN-beta Regulates Survival and Development of Transitional B Cells. J Immunol. 2017;199(8):2618–23. https://doi.org/10.4049/jimmunol.1700888.CrossRefPubMed

41.

Jacobs HM, Thouvenel CD, Leach S, Arkatkar T, Metzler G, Scharping NE, et al. Cutting Edge: BAFF Promotes Autoantibody Production via TACI-Dependent Activation of Transitional B Cells. J Immunol. 2016;196(9):3525–31. https://doi.org/10.4049/jimmunol.1600017.CrossRefPubMed

42.

Du SW, Jacobs HM, Arkatkar T, Rawlings DJ, Jackson SW. Integrated B Cell, Toll-like, and BAFF Receptor Signals Promote Autoantibody Production by Transitional B Cells. J Immunol. 2018;201(11):3258–68. https://doi.org/10.4049/jimmunol.1800393.CrossRefPubMed

43.

Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006;13(5):816–25. https://doi.org/10.1038/sj.cdd.4401850.CrossRefPubMed

44.

Aue A, Szelinski F, Weissenberg SY, Wiedemann A, Rose T, Lino AC, et al. Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility. Rheumatology (Oxford). 2020;59(11):3435–42. https://doi.org/10.1093/rheumatology/keaa187.CrossRef

45.

Patel ZH, Lu X, Miller D, Forney CR, Lee J, Lynch A, et al. A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. Hum Mol Genet. 2018;27(13):2392–404. https://doi.org/10.1093/hmg/ddy140.CrossRefPubMedPubMedCentral

46.

Wu YY, Kumar R, Iida R, Bagavant H, Alarcon-Riquelme ME. BANK1 Regulates IgG Production in a Lupus Model by Controlling TLR7-Dependent STAT1 Activation. PLoS ONE. 2016;11(5): e0156302. https://doi.org/10.1371/journal.pone.0156302.CrossRefPubMedPubMedCentral

47.

Xu W, Nair JS, Malhotra A, Zhang JJ. B cell antigen receptor signaling enhances IFN-gamma-induced Stat1 target gene expression through calcium mobilization and activation of multiple serine kinase pathways. J Interferon Cytokine Res. 2005;25(2):113–24. https://doi.org/10.1089/jir.2005.25.113.CrossRefPubMed

48.•

Chodisetti SB, Fike AJ, Domeier PP, Schell SL, Mockus TE, Choi NM, et al. Serine Phosphorylation of the STAT1 Transactivation Domain Promotes Autoreactive B Cell and Systemic Autoimmunity Development. J Immunol. 2020;204(10):2641–50. https://doi.org/10.4049/jimmunol.2000170. This study finds that autoimmune B cell responses can be distinguished from responses to foreign antigen by a dependence of the former, but not the latter, on a single phosphoyrlation site in STAT1.

49.

Kobayashi T, Shimabukuro-Demoto S, Yoshida-Sugitani R, Furuyama-Tanaka K, Karyu H, Sugiura Y, et al. The histidine transporter SLC15A4 coordinates mTOR-dependent inflammatory responses and pathogenic antibody production. Immunity. 2014;41(3):375–88. https://doi.org/10.1016/j.immuni.2014.08.011.CrossRefPubMed

50.

Thibault DL, Chu AD, Graham KL, Balboni I, Lee LY, Kohlmoos C, et al. IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J Clin Invest. 2008;118(4):1417–26. https://doi.org/10.1172/JCI30065.CrossRefPubMedPubMedCentral

51.

Xu W, Zhang JJ. Stat1-dependent synergistic activation of T-bet for IgG2a production during early stage of B cell activation. J Immunol. 2005;175(11):7419–24. https://doi.org/10.4049/jimmunol.175.11.7419.CrossRefPubMed

52.

Peng SL, Szabo SJ, Glimcher LH. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci U S A. 2002;99(8):5545–50. https://doi.org/10.1073/pnas.082114899.CrossRefPubMedPubMedCentral

53.

Stone SL, Peel JN, Scharer CD, Risley CA, Chisolm DA, Schultz MD et al. T-bet Transcription Factor Promotes Antibody-Secreting Cell Differentiation by Limiting the Inflammatory Effects of IFN-gamma on B Cells. Immunity. 2019;50(5):1172–87 e7. https://doi.org/10.1016/j.immuni.2019.04.004.

54.

Gomez Hernandez G, Morell M, Alarcon-Riquelme ME. The Role of BANK1 in B Cell Signaling and Disease. Cells. 2021;10(5). https://doi.org/10.3390/cells10051184.

55.

Georg I, Diaz-Barreiro A, Morell M, Pey AL, Alarcon-Riquelme ME. BANK1 interacts with TRAF6 and MyD88 in innate immune signaling in B cells. Cell Mol Immunol. 2020;17(9):954–65. https://doi.org/10.1038/s41423-019-0254-9.CrossRefPubMed

56.

Jiang SH, Athanasopoulos V, Ellyard JI, Chuah A, Cappello J, Cook A, et al. Functional rare and low frequency variants in BLK and BANK1 contribute to human lupus. Nat Commun. 2019;10(1):2201. https://doi.org/10.1038/s41467-019-10242-9.CrossRefPubMedPubMedCentral

57.

Ban T, Sato GR, Tamura T. Regulation and role of the transcription factor IRF5 in innate immune responses and systemic lupus erythematosus. Int Immunol. 2018;30(11):529–36. https://doi.org/10.1093/intimm/dxy032.CrossRefPubMed

58.

Pellerin A, Yasuda K, Cohen-Bucay A, Sandra V, Shukla P, Jr BKH et al. Monoallelic IRF5 deficiency in B cells prevents murine lupus. JCI Insight. 2021;6(15). https://doi.org/10.1172/jci.insight.141395.

59.

De S, Zhang B, Shih T, Singh S, Winkler A, Donnelly R, et al. B Cell-Intrinsic Role for IRF5 in TLR9/BCR-Induced Human B Cell Activation, Proliferation, and Plasmablast Differentiation. Front Immunol. 2017;8:1938. https://doi.org/10.3389/fimmu.2017.01938.CrossRefPubMed

60.

Song S, De S, Nelson V, Chopra S, LaPan M, Kampta K, et al. Inhibition of IRF5 hyperactivation protects from lupus onset and severity. J Clin Invest. 2020;130(12):6700–17. https://doi.org/10.1172/JCI120288.CrossRefPubMedPubMedCentral

61.

Li D, Matta B, Song S, Nelson V, Diggins K, Simpfendorfer KR et al. IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE. JCI Insight. 2020;5(2). https://doi.org/10.1172/jci.insight.124020.

62.

Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z, et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet. 2009;41(11):1234–7. https://doi.org/10.1038/ng.472.CrossRefPubMed

63.

Odhams CA, Roberts AL, Vester SK, Duarte CST, Beales CT, Clarke AJ, et al. Interferon inducible X-linked gene CXorf21 may contribute to sexual dimorphism in Systemic Lupus Erythematosus. Nat Commun. 2019;10(1):2164. https://doi.org/10.1038/s41467-019-10106-2.CrossRefPubMedPubMedCentral

64.

Blasius AL, Arnold CN, Georgel P, Rutschmann S, Xia Y, Lin P, et al. Slc15a4, AP-3, and Hermansky-Pudlak syndrome proteins are required for Toll-like receptor signaling in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A. 2010;107(46):19973–8. https://doi.org/10.1073/pnas.1014051107.CrossRefPubMedPubMedCentral

65.

Kobayashi T, Nguyen-Tien D, Ohshima D, Karyu H, Shimabukuro-Demoto S, Yoshida-Sugitani R, et al. Human SLC15A4 is crucial for TLR-mediated type I interferon production and mitochondrial integrity. Int Immunol. 2021;33(7):399–406. https://doi.org/10.1093/intimm/dxab006.CrossRefPubMed

66.

Sasawatari S, Okamura T, Kasumi E, Tanaka-Furuyama K, Yanobu-Takanashi R, Shirasawa S, et al. The solute carrier family 15A4 regulates TLR9 and NOD1 functions in the innate immune system and promotes colitis in mice. Gastroenterology. 2011;140(5):1513–25. https://doi.org/10.1053/j.gastro.2011.01.041.CrossRefPubMed

67.

Katewa A, Suto E, Hui J, Heredia J, Liang J, Hackney J, et al. The peptide symporter SLC15a4 is essential for the development of systemic lupus erythematosus in murine models. PLoS ONE. 2021;16(1): e0244439. https://doi.org/10.1371/journal.pone.0244439.CrossRefPubMedPubMedCentral

68.

Baccala R, Gonzalez-Quintial R, Blasius AL, Rimann I, Ozato K, Kono DH, et al. Essential requirement for IRF8 and SLC15A4 implicates plasmacytoid dendritic cells in the pathogenesis of lupus. Proc Natl Acad Sci U S A. 2013;110(8):2940–5. https://doi.org/10.1073/pnas.1222798110.CrossRefPubMedPubMedCentral

69.•

Heinz LX, Lee J, Kapoor U, Kartnig F, Sedlyarov V, Papakostas K, et al. TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9. Nature. 2020;581(7808):316–22. https://doi.org/10.1038/s41586-020-2282-0. Several molecules encoded by SLE-susceptibility loci are linked in a biochemical pathway in this report.

70.

Harris VM, Harley ITW, Kurien BT, Koelsch KA, Scofield RH. Lysosomal pH Is Regulated in a Sex Dependent Manner in Immune Cells Expressing CXorf21. Front Immunol. 2019;10:578. https://doi.org/10.3389/fimmu.2019.00578.CrossRefPubMedPubMedCentral

71.

Harris VM, Koelsch KA, Kurien BT, Harley ITW, Wren JD, Harley JB, et al. Characterization of cxorf21 Provides Molecular Insight Into Female-Bias Immune Response in SLE Pathogenesis. Front Immunol. 2019;10:2160. https://doi.org/10.3389/fimmu.2019.02160.CrossRefPubMedPubMedCentral

72.

Acharya M, Sokolovska A, Tam JM, Conway KL, Stefani C, Raso F, et al. alphav Integrins combine with LC3 and atg5 to regulate Toll-like receptor signalling in B cells. Nat Commun. 2016;7:10917. https://doi.org/10.1038/ncomms10917.CrossRefPubMedPubMedCentral

73.

Raso F, Sagadiev S, Du S, Gage E, Arkatkar T, Metzler G, et al. alphav Integrins regulate germinal center B cell responses through noncanonical autophagy. J Clin Invest. 2018;128(9):4163–78. https://doi.org/10.1172/JCI99597.CrossRefPubMedPubMedCentral

74.

Acharya M, Raso F, Sagadiev S, Gilbertson E, Kadavy L, Li QZ, et al. B Cell alphav Integrins Regulate TLR-Driven Autoimmunity. J Immunol. 2020;205(7):1810–8. https://doi.org/10.4049/jimmunol.1901056.CrossRefPubMedPubMedCentral

75.

Kim YM, Brinkmann MM, Paquet ME, Ploegh HL. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature. 2008;452(7184):234–8. https://doi.org/10.1038/nature06726.CrossRefPubMed

76.

Fukui R, Saitoh S, Kanno A, Onji M, Shibata T, Ito A, et al. Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. Immunity. 2011;35(1):69–81. https://doi.org/10.1016/j.immuni.2011.05.010.CrossRefPubMed

77.

Fukui R, Saitoh S, Matsumoto F, Kozuka-Hata H, Oyama M, Tabeta K, et al. Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing. J Exp Med. 2009;206(6):1339–50. https://doi.org/10.1084/jem.20082316.CrossRefPubMedPubMedCentral

78.

Majer O, Liu B, Woo BJ, Kreuk LSM, Van Dis E, Barton GM. Release from UNC93B1 reinforces the compartmentalized activation of select TLRs. Nature. 2019;575(7782):371–4. https://doi.org/10.1038/s41586-019-1611-7.CrossRefPubMedPubMedCentral

79.•

Majer O, Liu B, Kreuk LSM, Krogan N, Barton GM. UNC93B1 recruits syntenin-1 to dampen TLR7 signalling and prevent autoimmunity. Nature. 2019;575(7782):366–70. https://doi.org/10.1038/s41586-019-1612-6. This study highlights the importance of proper TLR7 trafficking for the termination of signaling and the prevention of autoimmunity.

80.

Kolhatkar NS, Scharping NE, Sullivan JM, Jacobs HM, Schwartz MA, Khim S, et al. B-cell intrinsic TLR7 signals promote depletion of the marginal zone in a murine model of Wiskott-Aldrich syndrome. Eur J Immunol. 2015;45(10):2773–9. https://doi.org/10.1002/eji.201545644.CrossRefPubMedPubMedCentral

81.

Tohme M, Maisonneuve L, Achour K, Dussiot M, Maschalidi S, Manoury B. TLR7 trafficking and signaling in B cells is regulated by the MHCII-associated invariant chain. J Cell Sci. 2020;133(5). https://doi.org/10.1242/jcs.236711.

82.

Mullard A. FDA approves AstraZeneca’s anifrolumab for lupus. Nat Rev Drug Discov. 2021;20(9):658. https://doi.org/10.1038/d41573-021-00139-y.CrossRefPubMed

83.

Boedigheimer MJ, Martin DA, Amoura Z, Sanchez-Guerrero J, Romero-Diaz J, Kivitz A, et al. Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-gamma monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus Sci Med. 2017;4(1): e000226. https://doi.org/10.1136/lupus-2017-000226.CrossRefPubMedPubMedCentral

84.

Bocharnikov AV, Keegan J, Wacleche VS, Cao Y, Fonseka CY, Wang G et al. PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. JCI Insight. 2019;4(20). https://doi.org/10.1172/jci.insight.130062.

85.

Ren HM, Lukacher AE, Rahman ZSM, Olsen NJ. New developments implicating IL-21 in autoimmune disease. J Autoimmun. 2021;122: 102689. https://doi.org/10.1016/j.jaut.2021.102689.CrossRefPubMed

86.

Chaichian Y, Wallace DJ. Innovative Trials and New Opportunities in SLE. Rheum Dis Clin North Am. 2021;47(3):481–99. https://doi.org/10.1016/j.rdc.2021.04.010.CrossRefPubMed

87.

Kolios AGA, Yoshida N, Tsokos GC. New therapeutic approaches in systemic lupus erythematosus. Curr Opin Rheumatol. 2021;33(2):181–9. https://doi.org/10.1097/BOR.0000000000000772.CrossRefPubMed

88.

Liossis SN, Staveri C. What’s New in the Treatment of Systemic Lupus Erythematosus. Front Med (Lausanne). 2021;8: 655100. https://doi.org/10.3389/fmed.2021.655100.CrossRef

89.

Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28(1):85–92. https://doi.org/10.1080/13543784.2019.1551358.CrossRefPubMed

90.

Celhar T, Lu HK, Benso L, Rakhilina L, Lee HY, Tripathi S, et al. TLR7 Protein Expression in Mild and Severe Lupus-Prone Models Is Regulated in a Leukocyte, Genetic, and IRAK4 Dependent Manner. Front Immunol. 2019;10:1546. https://doi.org/10.3389/fimmu.2019.01546.CrossRefPubMedPubMedCentral

91.

Corzo CA, Varfolomeev E, Setiadi AF, Francis R, Klabunde S, Senger K et al. The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells. Sci Signal. 2020;13(634). https://doi.org/10.1126/scisignal.aaz1053.

92.

Dudhgaonkar S, Ranade S, Nagar J, Subramani S, Prasad DS, Karunanithi P, et al. Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity. J Immunol. 2017;198(3):1308–19. https://doi.org/10.4049/jimmunol.1600583.CrossRefPubMed

93.

Murphy M, Pattabiraman G, Manavalan TT, Medvedev AE. Deficiency in IRAK4 activity attenuates manifestations of murine Lupus. Eur J Immunol. 2017;47(5):880–91. https://doi.org/10.1002/eji.201646641.CrossRefPubMedPubMedCentral

94.

Nanda SK, Lopez-Pelaez M, Arthur JS, Marchesi F, Cohen P. Suppression of IRAK1 or IRAK4 Catalytic Activity, but Not Type 1 IFN Signaling, Prevents Lupus Nephritis in Mice Expressing a Ubiquitin Binding-Defective Mutant of ABIN1. J Immunol. 2016;197(11):4266–73. :https://doi.org/10.4049/jimmunol.1600788.

95.

Winkler A, Sun W, De S, Jiao A, Nusrat Sharif M, Symanowicz PT, et al. The IRAK4 kinase inhibitor PF-06650833 blocks inflammation in preclinical models of rheumatologic disease and in humans enrolled in a randomized clinical trial. Arthritis Rheumatol. 2021. https://doi.org/10.1002/art.41953.CrossRefPubMed

96.

Hjorton K, Hagberg N, Israelsson E, Jinton L, Berggren O, Sandling JK, et al. Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor. Arthritis Res Ther. 2018;20(1):238. https://doi.org/10.1186/s13075-018-1702-0.CrossRefPubMedPubMedCentral

97.

Ban T, Kikuchi M, Sato GR, Manabe A, Tagata N, Harita K, et al. Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease. Nat Commun. 2021;12(1):4379. https://doi.org/10.1038/s41467-021-24609-4.CrossRefPubMedPubMedCentral

98.

Dong X, Antao OQ, Song W, Sanchez GM, Zembrzuski K, Koumpouras F, et al. Type I Interferon-Activated STAT4 Regulation of Follicular Helper T Cell-Dependent Cytokine and Immunoglobulin Production in Lupus. Arthritis Rheumatol. 2021;73(3):478–89. https://doi.org/10.1002/art.41532.CrossRefPubMed

Titel: TLR7 Signaling in Lupus B Cells: New Insights into Synergizing Factors and Downstream Signals
verfasst von: Anne B. Satterthwaite
Publikationsdatum: 01.11.2021
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 11/2021
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-021-01047-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

TLR7 Signaling in Lupus B Cells: New Insights into Synergizing Factors and Downstream Signals

Abstract

Purpose of the Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of the Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Update Innere Medizin